Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

The “No Kings” protest on the square in Mount Gilead Saturday was maintained peacefully from noon to 2 p.m. It was one of the thousands of protests held around the nation. Many drivers passing by ...

Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.

The National Weather Service issued a report at 9:14 p.m. EDT on Tuesday for strong thunderstorms until 10 p.m. EDT for St.

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...

Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.

Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...

A man who could be facing the death penalty in the death of a Morrow County sheriff’s deputy had his second arraignment ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now. Nevertheless, the company suffered a significant setback after the US Food and Drug Administration put on hold ...

Gilead is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in ...